Clinical Trials Sponsored by Tom Baker Cancer Centre

Total 380 results

University of Calgary
Tom Baker Cancer Centre

Completed

Exercise, Nutrition, and Palliative Care in Advanced Lung Cancer (ENPAL) (ENPAL)

Advanced Lung Cancer

Canada
University of Calgary
Tom Baker Cancer Centre

Completed

PET/CT: Role in Detecting Unknown Primary Head and Neck Cancer

Head and Neck Cancer

Canada
AHS Cancer Control Alberta
Tom Baker Cancer Centre

Recruiting

A Research Study to Collect Patient Reported Outcomes Using Electronic Surveys

Breast Cancer | Colorectal Cancer

Canada
AHS Cancer Control Alberta
Tom Baker Cancer Centre

Recruiting

A Multicentre, Non-Blinded Study Exploring Self-Administration of Chemotherapy in the Home Environment (EASE)

Myeloma | Myeloma Multiple

Canada
AHS Cancer Control Alberta
Tom Baker Cancer Centre

Terminated

GEMHDM2014 : Gem-HDM HDT and ASCT for Relapsed/ Refractory Lymphoma (GEMHDM2014)

Follicular Lymphoma | Hodgkin's Lymphoma - Relapsed/Refractory | Non-Hodgkin's Lymphoma - Aggressive

Canada
AHS Cancer Control Alberta
Tom Baker Cancer Centre

Recruiting

Pilot Trial for Treatment of Recurrent Glioblastoma

Glioblastoma | Recurrent Glioblastoma | Recurrent Disease

Canada
AHS Cancer Control Alberta
Tom Baker Cancer Centre

Active, not recruiting

Pembrolizumab in Patients With Poor-Prognosis Carcinoma of Unknown Primary Site (CUP) (CUP)

Carcinoma of Unknown Primary

Canada
AHS Cancer Control Alberta
Tom Baker Cancer Centre

Withdrawn

A Study of Trifluridine/Tipiracil in Triple Negative Metastatic Breast Cancer (TACTIC)

Metastatic Triple Negative Breast Cancer

Canada
AHS Cancer Control Alberta
Tom Baker Cancer Centre

Recruiting

Study of Niacin in Glioblastoma

Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype

Canada
AHS Cancer Control Alberta
Abbott; Tom Baker Cancer Centre

Completed

Study of ABT-888 in Combination With Bortezomib and Dexamethasone in Patients With Relapsed Refractory Myeloma

Multiple Myeloma

Canada
AHS Cancer Control Alberta
Cross Cancer Institute; Tom Baker Cancer Centre

Recruiting

p16+ Oropharyngeal Cancer Radiation Optimization Trial Reducing Elective Treatment Volumes (PROTEcT) (PROTEcT)

Squamous Cell Carcinoma of the Oropharynx

Canada
Alberta Health services
Tom Baker Cancer Centre

Completed

Bioavailability and Effectiveness of Transdermally Administered Morphine

Pain | Cancer

Canada
Alberta Health services
Tom Baker Cancer Centre

Unknown

Frameless Stereotactic Radiosurgery for Brain Metastases

Brain Metastases

Canada
Alberta Health services
Tom Baker Cancer Centre

Unknown

The eCALM Study - An Online Mindfulness-Based Stress Reduction Program for Individuals Living With Cancer in Alberta (eCALM)

Cancer | Mindfulness-Based Stress Reduction (MBSR)

Canada
Alberta Health Services, Calgary
University of Calgary; Tom Baker Cancer Centre

Not yet recruiting

Prophylactic LYMphatic Reconstruction (LYMbR) to Prevent Lymphedema After Node Dissection for Cutaneous Malignancies (LYMbR)

Lymphedema of Limb | Malignant Skin Neoplasm

Canada
University of Calgary
Alberta Cancer Foundation; University of Alberta; Cross Cancer Institute; Tom Baker...

Active, not recruiting

A Tailored Exercise Oncology Program for Neuro-Oncology Patients (ACE-Neuro)

Cancer | Brain Tumor, Primary

Canada
University Health Network, Toronto
Tom Baker Cancer Centre; Southlake Regional Health Centre; Scarborough Rouge...

Completed

ADT Exercise Trial and Economic Analysis (ADTExRCT)

Prostate Cancer

Canada
M.D. Anderson Cancer Center
Bayer

Not yet recruiting

Phase 2 Study to Evaluate the Efficacy of Regorafenib in Specific GIST Mutation Subsets (KIT Exon 17, 18, or 14 Mutation and SDHB Deficient GIST) in the Post-imatinib Second-line Setting.

Gastrointestinal Stromal Tumors

United States
M.D. Anderson Cancer Center
Bayer

Completed

Sorafenib Plus 5-Azacitidine Initial Therapy of Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MS) With FLT3-ITD Mutation

Leukemia

United States
M.D. Anderson Cancer Center
Bayer

Completed

Rituximab Plus Sargramostim (GM-CSF) In Patients With Chronic Lymphocytic Leukemia

Leukemia

United States
M.D. Anderson Cancer Center
Bayer

Completed

CFAR Study in Patients With Chronic Lymphocytic Leukemia

Leukemia | Chronic Lymphocytic Leukemia

United States
M.D. Anderson Cancer Center
Bayer

Completed

Immuno-Augmentation With GM-CSF of Pneumococcal Vaccine in Chronic Lymphocytic Leukemia Patients

Leukemia

United States
M.D. Anderson Cancer Center
Bayer

Completed

Evaluating the Use of Fibrin Tissue Adhesive in Melanoma Patients

Melanoma

United States
M.D. Anderson Cancer Center
Bayer

Active, not recruiting

Phase 2 Study of PI3K Inhibitor Copanlisib in Combination With Fulvestrant in Selected ER+ and/or PR+ Cancers With PI3K (PIK3CA, PIK3R1) and/or PTEN Alterations

Ovarian Cancer | Endometrial Cancer

United States
M.D. Anderson Cancer Center
Bayer

Completed

Trial of Ra-223 Dichloride in Combination With Hormonal Therapy and Denosumab in the Treatment of Patients With Hormone-Positive Bone-Dominant Metastatic Breast Cancer

Breast Cancer

United States
M.D. Anderson Cancer Center
Bayer

Terminated

Sorafenib and Thoracic Radiation for Patients With Non-Small Cell Lung Cancer

Lung Cancer

United States
M.D. Anderson Cancer Center
Bayer

Completed

BAY 43-9006 in Previously Untreated Patients With Non-Small Cell Lung Cancer (NSCLC)

Lung Cancer

United States
M.D. Anderson Cancer Center
Bayer

Withdrawn

Phase II Sorafenib With Radiation and Temozolomide in Newly Diagnosed Glioblastoma or Gliosarcoma

Glioblastoma | Gliosarcoma
Fox Chase Cancer Center
Bayer

Withdrawn

Sorafenib in Hormone Naïve Biochemical Recurrence of Prostate Cancer

Prostate Cancer

United States
M.D. Anderson Cancer Center
Bayer

Completed

G-CSF Versus G-CSF Plus GM-CSF for Stem Cell Mobilization in NHL Patients

Lymphoma

United States
M.D. Anderson Cancer Center
Bayer

Completed

Herceptin and GM-CSF for Metastatic Breast Cancer

Breast Cancer

United States
M.D. Anderson Cancer Center
Bayer

Completed

Cyclophosphamide, Fludarabine, Alemtuzumab, and Rituximab (CFAR) for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

Chronic Lymphocytic Leukemia

United States
Jonsson Comprehensive Cancer Center
Bayer

Completed

Sorafenib Tosylate Following a Liver Transplant in Treating Patients With Liver Cancer

Localized Resectable Adult Primary Liver Cancer | Localized Unresectable Adult Primary Liver Cancer | Recurrent Adult Primary Liver Cancer | Adult Primary Hepatocellular Carcinoma

United States
M.D. Anderson Cancer Center
Bayer

Completed

Phase I Dose Escalation of Monthly Intravenous Ra-223 Dichloride in Osteosarcoma

Sarcoma

United States
M.D. Anderson Cancer Center
Bayer

Terminated

Phase I Portion of Phase I/II Sorafenib With Radiation and Temozolomide in Newly Diagnosed Glioblastoma or Gliosarcoma

Glioblastoma | Gliosarcoma

United States
M.D. Anderson Cancer Center
Bayer

Completed

Phase I-II Study of Idarubicin, Cytarabine, and Sorafenib (BAY43-9006)

Acute Myeloid Leukemia | AML | Myelodysplastic Disorders

United States
M.D. Anderson Cancer Center
Bayer

Completed

FCR Plus Sargramostim (GM-CSF) as Frontline Therapy for Symptomatic Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia

United States
National Cancer Center, Korea
Bayer

Terminated

Study of Sorafenib Maintenance in Patients With ED-SCLC After Response to Induction Chemotherapy

Small Cell Lung Cancer

Korea, Republic of
M.D. Anderson Cancer Center
Bayer

Completed

Campath-1H Plus Rituximab for CD52- and CD20- Positive Refractory or Relapsed Chronic Lymphoid Disorders

Chronic Lymphocytic Leukemia

United States
M.D. Anderson Cancer Center
Bayer

Terminated

Autologous and Allogenic Transplantation With Campath-1H for T-Cell Lymphoma

Lymphoma

United States
University Health Network, Toronto
Sunnybrook Health Sciences Centre; Tom Baker Cancer Centre; Vancouver Coastal... and other collaborators

Active, not recruiting

Sexual Health and Rehabilitation eClinic (SHAReClinic)

Sexual Dysfunction | Prostate Cancer

Canada
Tom Baker Cancer Centre
University of Calgary; Canadian Association of General Surgeons; MSI Foundation

Completed

Reconstruction Following Pancreaticoduodenectomy: A Randomized Clinical Trial of Pancreaticojejunostomy vs Pancreaticogastomy

Periampullary Cancer | Pancreas Cancer

Canada
British Columbia Cancer Agency
Princess Margaret Hospital, Canada; London Regional Cancer Program, Canada; Tom...

Not yet recruiting

Single vs. Multiple Fraction Trial of Stereotactic Ablative Radiotherapy for Comprehensive Treatment of Oligometastases/Progression

Quality of Life | Toxicity Due to Radiotherapy | Oligometastatic Disease | Oligoprogression

Canada
University of Alberta
Alberta Health services; University of Calgary; Cross Cancer Institute; Tom Baker...

Recruiting

Alberta Cancer Exercise Hybrid Effectiveness-Implementation Study (ACE)

Neoplasms

Canada
Judge Baker Children's Center

Completed

Behavioral and Affective Skills in Coping (BASIC) Open Trial (BASIC)

Anxiety Disorders | Disruptive Behavior Disorders | Depressive Disorders

United States
Memorial Sloan Kettering Cancer Center
Bayer

Recruiting

A Study to Test Radium-223 With Docetaxel in Patients With Prostate Cancer

Prostate Cancer

United States, Netherlands, Spain, Brazil
Memorial Sloan Kettering Cancer Center
Bayer

Active, not recruiting

Regorafenib in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma

Adenoid Cystic Carcinoma

United States
Memorial Sloan Kettering Cancer Center
Bayer

Completed

A Study of Copanlisib and Ibrutinib in Mantle Cell Lymphoma

Mantle Cell Lymphoma (MCL)

United States
UNC Lineberger Comprehensive Cancer Center
Bayer

Completed

Regorafenib+FOLFIRI Versus Placebo+FOLFIRI as 2nd Line Tx in Metastatic Colorectal Cancer

Colorectal Cancer Metastatic

United States, Ireland
Memorial Sloan Kettering Cancer Center
Bayer

Completed

Sorafenib for Patients With Metastatic or Recurrent Esophageal and Gastroesophageal Junction Cancer

Esophageal Cancer | Gastroesophageal Junction Cancer

United States

Clinical Trials Sponsored by Tom Baker Cancer Centre

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Armenia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations